Introduction {#s1}
============

Lung cancer is the leading cause of global cancer deaths in recent decades \[[@B1]\]. Human lung cancer contains two histological types, small-cell lung cancer (SCLC) and non-small lung cancer (NSCLC). The latter comprises the majority of lung cancer and has an increasing incidence and mortality in the last two decades worldwide. DNA methylation is an epigenetic modification of the genome and methylation associated with silencing can affect genes expression in cellular pathways \[[@B2]\]. The epigenetic alterations are early and frequent events occurred in carcinogenesis. O^6^-methylguanine-DNA methyl-transferase (MGMT) is a DNA damage reversal protein against DNA adduct formation of carcinogens \[[@B3],[@B4]\]. It can protect cells from the carcinogenic effects of alkylating agents by removing adducts from the O^6^ position of guanine \[[@B5]\]. Therefore, the repair capacity of the MGMT protein helps decrease the probability so that the damaged guanine becomes a mutagenic site. Methylation of *MGMT* gene promoter has been associated with loss or decrease of *MGMT* expression in tumor tissues of various cancers, including lung tumors \[[@B6]-[@B8]\].

Taken together, methylation of *MGMT* gene has been considered as potentially useful candidate biomarker for early detection of lung cancer. Many studies had also shown that methylation of the gene can be found in clinical samples, such as tissues, serum and bronchoalveolar lavage fluid (BALF) of NSCLC \[[@B9]-[@B11]\].

The purpose of this study was to understand the difference of the prevalence of aberrant promoter methylation of *MGMT* in NSCLC tissue from control. We conducted a meta-analysis using available data in the literature on the basis of *MGMT* promoter methylation and NSCLC to better identify the association between *MGMT* promoter methylation and NSCLC.

Materials and Methods {#s2}
=====================

Selection criteria and study search {#s2.1}
-----------------------------------

We searched the electronic databases online including Pubmed, EMBASE, Ovid, ISI Web of Science, Elsevier and CNKI database, using the search terms "*MGMT*", "NSCLC" and "methylation". The following search strategy was performed in Pubmed "NSCLC" (MESH), "methylation" and "*MGMT* or O^6^-methylguanine-DNA methyl-transferase" to collect eligible articles. The search was limited to articles published in English and Chinese. Similar searches were performed in other databases. The search was updated until June 1, 2013.

Studies selected had to meet the following criteria: (a) The study was about *MGMT* methylation and NSCLC. (b) The authors offered a measure of the association either as an effect estimate with 95% CI and OR, or sufficient data in the original article to calculate it. (c) *MGTM* methylation status was examined using methylation-specific PCR (MSP) or real-time quantitative MSP (Q-MSP). (d) Specimens of NSCLC were surgically respected primary tumor sample and the styles of control were composed of plasma or non-cancerous lung tissues (NLT) including autologous control and heterogeneous control.

Studies were excluded according the following criteria: (a) The study did not provide control information. (b) The articles were repetitively reported, (c) The articles researched chromate lung cancer, brain metastases of lung cancers and malignant pleural mesothelioma \[[@B7],[@B12],[@B13]\]. Firstly, we evaluated whether a study met the inclusion criteria by title and abstract of initial searching articles. Then all the potentially relevant articles were evaluated by accessing full-text paper. The selection procedure of studies was illustrated in statement flow chart ([Figure 1](#pone-0072633-g001){ref-type="fig"}).

![Flow diagram of the stepwise selection from associated studies.](pone.0072633.g001){#pone-0072633-g001}

Abstraction of Data and Quality Assessment {#s2.2}
------------------------------------------

All the data were independently abstracted by three authors (Changmei Gu, Cheng Lu, and Hao Shi) with the use of standardized data-extraction forms. For each study, the following characteristics were extracted: first author's name, year of publication, the study country, ethnicity, age, sample size, type of control, the method for methylating detection, and status of *MGMT* methylation were collected using standard data extraction forms. If there were disagreements, we discussed with Meixia Lu and Jiachun Lu repeatedly, until a consensus. To ensure the transparent and complete reporting of this meta-analysis, we designed and checked selected studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[14\] statement.

Statistical Methods {#s2.3}
-------------------

The ORs and 95% CIs were abstracted or calculated to evaluate the strength of the association between *MGMT* promoter methylation and NSCLC risk. Summary of OR was acquired from all studies or calculated with the data in selected studies.

We, then, investigated between-study heterogeneity by using Cochran's Q test with a significance level of *P* value less than 0.1 and heterogeneity was also examined using *I* ^2^ statistic \[15\], which is a quantitative measure of inconsistency across studies. If *I* ^2^ \> 50% or *P* \< 0.1 is considered as a measure of severe heterogeneity, then the random-effects model was used to calculate summary OR according to the Der-Simonian Laird method; otherwise, the fixed-effects model (Matel--Haenszel method) was applied\[16\]. τ^2^ was used to determine how much heterogeneity was explained by subgroup differences. The meta-regression was performed to explore the source of heterogeneity based on ethnicity (Asian and Caucasian), publication year, style of control (autogenous or heterogeneous), method (MSP or Q-MSP), and sample size. Subgroup analyses were performed according to ethnicity (Asian and Caucasian), control style (autogenous or heterogeneous) and method of methylation detection (MSP or Q-MSP) [in consideration of]{.ul} the source of heterogeneity. Sensitivity analyses were also performed to assess the contributions of each study on the overall result by omitting one study at a time. The funnel plot asymmetry was used to evaluate the evidence of publication bias. Peter's test was applied to quantitatively evaluate the evidence for publication bias \[17\]. Fail-safe number (N~fs~) adopted by Rosenthal \[28\] is considered to be a useful indicator of leaning \[18\]. The meta-trim method was used to re-estimate the effect size when there was possible bias. All *P* values are two-tailed with a significant level at 0.05. In forest plot displayed in [Figure 2](#pone-0072633-g002){ref-type="fig"}, the size of the box for each study was inversely proportional to the variance of the log relative risk, and the horizontal lines represent 95% CI.

![Forest plot of MGMT methylation in tumor tissue verse control group between *MGMT* promoter methylation and NSCLC.](pone.0072633.g002){#pone-0072633-g002}

All statistical analyses were conducted by using the Meta package (version 2.2-1) in R (version 3.0, <http://www.r-project.org/>).

Results {#s3}
=======

Study Characteristics {#s3.1}
---------------------

The electronic search found that 145 potentially relevant studies were initially identified. These studies were further screened based on inclusion and exclusion criteria. A total of 18 studies (2001-2011) were included in the analysis ([Figure 1](#pone-0072633-g001){ref-type="fig"}). In these studies, 6 studies were conducted in Asia (1 in Japan and 5 in China) and the remaining 11 were in the USA and 1 in the Netherlands.

Among the 18 retrieved studies, 14 studies used methylation-specific polymerase chain reaction (MSP) and 4 studies used real-time quantitative MSP (Q-MSP) to explore *MGMT* methylation in NSCLC tissue and control. There were two control styles, including autogenous control (the tissues from the patients themselves) and heterogeneous control (i.e Plasma, tissue, and bronchoalveolar lavage fluid from other individuals). The main characteristics of these studies were presented in [Table 1](#pone-0072633-t001){ref-type="table"}.

10.1371/journal.pone.0072633.t001

###### Characteristics of studies included in this meta-analysis.

                                                Gender                   Patients   Control   Control   Control
  ------------------ ------ ------- ----------- -------- ------- ------- ---------- --------- --------- ---------
  Zochbauer\[19\]    2001   USA     Caucasian   76/31    28-81   MSP     22/107     0/104     A         tissue
  Brabender\[20\]    2003   USA     Caucasian   68/22    63.3    Q-MSP   34/90      16/90     A         tissue
  Brabender\[20\]    2003   USA     Caucasian   NA       NR      Q-MSP   34/90      0/10      H         tissue
  Guo\[9\]           2004   USA     Caucasian   NA       42-83   MSP     14/20      1/15      A         tissue
  Guo\[9\]           2004   USA     Caucasian   NA       42-83   MSP     14/20      11/20     A         BALF
  Topaloglu\[21\]    2004   USA     Caucasian   NA       NA      Q-MSP   12/31      7/31      A         tissue
  Russo\[22\]        2005   USA     Caucasian   NA       NA      MSP     18/33      6/33      A         serum
  Safar\[23\]        2005   USA     Caucasian   NA       67      MSP     4/32       1/32      A         tissue
  Vallbohmer\[24\]   2006   USA     Caucasian   69/22    63      MSP     35/91      16/91     A         tissue
  Yanagawa\[25\]     2007   Japan   Asian       72/29    39-86   MSP     14/101     2/101     A         tissue
  Belinsky\[26\]     2007   USA     Caucasian   49/23    37-80   MSP     11/72      4/72      A         serum
  Feng\[27\]         2008   USA     Caucasian   24/23    64.3    MSP     4/49       1/49      A         tissue
  Lin\[28\]          2009   China   Asian       NA       NA      MSP     1/67       0/14      H         tissue
  De Jong\[29\]      2009   NE      Caucasian   NA       40-70   Q-MSP   1/10       0/18      H         tissue
  Liu\[30\]          2010   China   Asian       58/40    32-68   MSP     31/98      0/98      H         tissue
  Jin\[31\]          2010   China   Asian       83/11    32-75   MSP     16/94      2/94      A         tissue
  Zhang\[32\]        2011   China   Asian       58/20    35-80   MSP     4/78       2/78      A         tissue
  Hang\[33\]         2011   China   Asian       64/32    33-70   MSP     26/77      0/20      H         tissue

Abbreviation: A: Autologos control(the control from the NSCLC themselves); BALF: bronchoalveolar lavage fluid; H: Heterogeneous control(the control from other individuals, including serum, bronchoalveolar lavage or tissue); M+: The number of methylation; MSP: methylation-specific polymerase chain reaction; N: number of total; NA: not applicable; NE: Netherlands; Q-MSP: real-time quantitative methylation-specific polymerase chain reaction

There are 1, 160 NSCLC tumor tissues and 970 controls. The frequencies of *MGMT* promote methylation ranged from 1.5% to 70.0% (median 26.1%) in NSCLC tissue and 0.0% to 55.0% (median 2.4%) in non-cancerous control, respectively, which indicated the methylation frequency in cancer tissue was much higher than that in the control group. Under the random-effects model, the pooled OR of *MGMT* methylation in NSCLC tissue was 4.43 (95% CI: 2.85, 6.89), in comparison with control group ([Figure 2](#pone-0072633-g002){ref-type="fig"}).

Meta-regression and subgroup analyses {#s3.2}
-------------------------------------

Considering the existence of heterogeneity in the meta-analysis (*I* ^2^=32.0%, *P*= 0. 095), the meta-regression was performed for finding the source of heterogeneity. The restricted maximum likelihood modification was used to estimate between study variances. As the restriction to access raw data, we assumed the source of heterogeneity may appear from the year of publication, ethnicity, type of control, detection method and sample size. The results showed that the sources of the heterogeneity were control style (*P* = 0.073) and detection method (*P* = 0.094). Other factors such as sample size, year of publication, and ethnicity could not explain the heterogeneity ([Table 2](#pone-0072633-t002){ref-type="table"}).

10.1371/journal.pone.0072633.t002

###### Mixed-effects model of meta-regression analysis.

                                    95%CI              
  ------------- --------- --------- --------- -------- -------
  Year          -0.1964   -1.4009   -0.4712   0.0784   0.161
  Control       1.4501    1.7915    -0.1364   3.0365   0.073
  Ethnicity     0.9485    1.3741    -0.4044   2.3015   0.169
  Method        -0.8260   -1.6752   -1.7925   0.1404   0.094
  Sample size   0.0014    0.4581    -0.0046   0.0075   0.065

With these observations, we performed subgroup analyses based on control style and detection method. The OR in the heterogeneous control subgroup was 20.45 (95% CI: 5.83, 71.73; fixed-effects model), while it was 4.16 (95% CI: 3.02,5.72; fixed-effects model) in the autologous control subgroup. *I* ^2^ changed to 16.6% and 34.0% in those subgroups, respectively, compared with 32% of the total. Stratification by control style showed that the OR in the heterogeneous control subgroup was higher than that in the autologous control subgroup. After stratification by detection method, the OR was 5.31 (95% CI: 3.00, 9.41; random-effects model) in MSP subgroup and 3.06 (95% CI: 1.75, 5.33; fixed-effects model) in Q-MSP subgroup ([Table 3](#pone-0072633-t003){ref-type="table"}).

10.1371/journal.pone.0072633.t003

###### Subgroup analysis of the association between *MGMT* promoter methylation and NSCLC.

                  Tumor   Control   M-H pooled OR^b^   D+L pooled OR^a^   Heterogeneity                                              
  --------------- ------- --------- ------------------ ------------------ --------------------- --------------------- ------ ------- ----------
  Control group                                                                                                                      
  Auologous       202      818      69                 810                4.16 (3.02, 5.72)     3.74 (2.54, 5.51)     16.6   0.276   0.080
  Heterogeneous    93      342       0                 160                20.45 (5.83, 71.73)   11.18 (2.14, 58.35)   34.0   0.194   1.208
  Ethnicity                                                                                                                          
  Asian            92      515       6                 405                10.96 (5.20, 23.14)   7.36 (2.33, 23.19)    45.1   0.105   0.8807
  Caucasian       203      645      63                 565                4.00 (2.85, 5.60)     3.49 (2.37, 5.14)     8.9    0.358   0.0418
  Method                                                                                                                             
  MSP             214      939      46                 821                6.17 (4.28, 8.91)     5.31 (3.00, 9.41)     40.2   0.060   0.4155
  Q-MSP            81      221      23                 149                3.06 (1.75, 5.33)     2.84 (1.62, 5.00)     0.0    0.674   \<0.0001
  Total           295     1160      69                 970                5.10 (3.77, 6.91)     4.43 (2.85, 6.89)     32.0   0.095   0.2476

D+L pooled OR^a^: the result from random-effects model;M-H pooled OR^b^: the result from fixed-effects model.

Sensitivity analysis {#s3.3}
--------------------

To determine the effects of omitting a single study at a time on the overall effect, the sensitivity analysis was performed. Omission of a single study changed the overall OR from 3.85 (95% CI: 2.66, 5.56) to 4.87 (95% CI: 2.96, 8.02) using the random-effects model, which demonstrated that no single sensitivity analysis existed ([Figure 3](#pone-0072633-g003){ref-type="fig"}).

![Sensitivity analysis by omitting a single study at a time on the overall effect.](pone.0072633.g003){#pone-0072633-g003}

Publication bias {#s3.4}
----------------

A funnel plot of methylation status of tumor versus control showed that there were two studies exceed the 95% confidence limits as shown in [Figure 4](#pone-0072633-g004){ref-type="fig"}. However, no publication bias was detected by using Peter's test (*P* = 0.624). We also used a fail-safe number (N~fs~) to assess the efficacy of meta-analysis (*Z* = 45.63, N~fs0.\ 05~ = 756.12, N~fs0.\ 01~ = 365.52), which indicated a slight publication bias in the meta-analysis.

![Funnel plot for assessment of publication bias.\
**Each hollow point represents a separate study for the indicated association**. The area of the hollow point reflects the weight (inverse of the variance). Horizontal line stands for the mean magnitude of the effect.](pone.0072633.g004){#pone-0072633-g004}

Discussion {#s4}
==========

Aberrant methylation of promoter regions in DNA repair genes is a key event in the formation and progression of cancer. It was concluded that genes methylation was potentially a new generation of cancer biomarker \[34\]. Epigenetic change of CpG islands in the gene promoter region is an important reason for gene dysfunction \[35\], which can lead to the transcription of the gene down or stops \[36\].

*MGMT* promoter methylation is very common in the primary NSCLC, which has been reported in some studies. However, the results about the association between the status of *MGMT* methylation and NSCLC were inconsistent. The OR values fluctuated from 0.65 \[28\] to 114.98 \[24\], so we performed this meta-analysis to identify the association between *MGMT* promoter methylation and NSCLC.

A total of 18 studies including 1, 160 tumor tissues and 970 controls were involved in the meta-analysis. The frequencies of *MGMT* promote methylation ranged from 1.5% to 70.0% (median; 26.1%) in NSCLC tissue and 0.0% to 55.0% (median; 2.4%) in non-cancerous control, respectively. The findings indicated that the methylation frequency in cancer tissue was much higher than that in the control group. *MGMT* methylation had an increased risk in tumor tissue (OR = 4.43; 95% CI: 2.85, 6.89) in comparison with non-cancerous samples including plasma, tissue, and bronchoalveolar lavage fluid. This finding was consistent with other studies \[10,25\]. Furthermore, subgroup analysis of control style showed that an OR was 20.45 (95% CI: 5.83, 71.73; fixed-effects model) in the heterogeneous control subgroup verse 4.16 (95% CI: 3.02, 5.72; random-effects model) in the autologous tissues subgroup, indicating that the OR of methylation in heterogeneous control group was higher than that in the autologous control group. It suggested that *MGMT* gene promoter methylation was a frequent event in NSCLC, but it rarely happened in the non-tumor group. Stratification analysis by different methods of methylation detection showed that the OR for the MSP subgroup was higher than that for Q-MSP subgroup.

Sensitivity analysis was performed to determine the effects when omitting a single study at a time on the overall effect. The analytic results demonstrated that no single study could affect the summarized OR. In addition, the shape of the funnel plot did not show any evidence of funnel plot asymmetry and no publication bias was detected.

The current meta-analysis has some limitations. Firstly, selection bias is inevitable due to the strategy restricted to articles published in English or Chinese. Secondly, although the total sample sizes in the meta-analysis were not more than 1, 000, the results maybe have still no vigorous power. Thirdly, we did not study the methylation status in histological subtypes, smoking and different clinical stages because of limitation of insufficient raw materials.

In conclusion, *MGMT* gene is an important DNA repair gene on maintaining the integrity of the genome. Aberrant *MGMT* promoter methylation may be associated with the occurrence and development of NSCLC. This meta-analysis identified a strong association between *MGMT* promoter methylation and NSCLC. Prospective studies should be required to confirm the results in the future.
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